RE: just for you lot21 Feb 2022 21:08
Talking about rubbish on this bb this post from Beforegolf is worth sharing again amongst some of the drivel here.....
Beforegolf Posts: 1,237
Price: 27.18 No Opinion
RE: just for you lotToday 20:21
"someone in the guild has had contact with the company. It's their notes and not verbatim
Company feedback
Sprinter: On the positive side the 30% to 40% reduction in mortality is an excellent signal and on it's own, in the early stages of COVID would have been amongst the best results available. In the phase 2, I suspect there were no patients who were vaxed, on Remdisivir nor steroids. however in the phase 3, with 90% on steroid and probably 25%/30% vaxed (given when the trial ran) and a number on Remdisivir.
However, they have not yet done the data digging to see what effect excluding these groups would have made. Should be done in a few weeks.
Activ -2. They haven't as yet seen the data but are chasing it hard. NIH 'warp speed' (and Barda) are going through some changes, including confirming a new comparator, however they did see enough positive signal to put it into the phase 3. Hopes to know in a few weeks but not in their hands, so could be longer. This would end up being our key 'early' use trial.
Platform trials - Tom and Sir Stephen are well connected at the top of COVID research so they are leading, over the next few weeks, in talking with the platform trials (including Recovery, Activ-3 and Remapcap amongst others). They hope to zoom in on Mortality, but by nature these will need to be much bigger trials (1-2000) which in reality only the platform trials can deliver. Still 1000 a week dying and if they could save 30%/40% it would be significant. If they do get the go ahead, I suspect it will be somewhere between 4 - 8 weeks to get the drug etc into the right places for the trial to start.
Funding: Activ-2 and the other platform trials are all Govt funded, so they have no intention or need to raise funds. He also confirmed they have enough drug, placebo, nebulisers etc manufactured to easily cover any platform trial.
On a general note, again stressed the depth and quality of the safety data.It has taken a few hours of discussion with this souce to agree a release to the manic crowd of LSE. I do not care one iota what you do with it or think, but I hope it helps some possibly depressed people see the light at the end of the tunnel"
Recommend (52)